145 related articles for article (PubMed ID: 21858491)
21. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.
Holló G; Katsanos A
Expert Opin Drug Saf; 2015 Apr; 14(4):609-17. PubMed ID: 25640746
[TBL] [Abstract][Full Text] [Related]
22. [Tafluprost (Saflutan) ophthalmic use].
Duh D; Tanret I
J Pharm Belg; 2013 Jun; (2):41-2. PubMed ID: 23798185
[No Abstract] [Full Text] [Related]
23. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
Uusitalo H; Kaarniranta K; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():7-13. PubMed ID: 18752509
[TBL] [Abstract][Full Text] [Related]
24. Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.
Keating GM
Clin Drug Investig; 2016 Jun; 36(6):499-508. PubMed ID: 27225879
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of preserved Tafluprost 0.0015% in lowering intraocular pressure.
Paul C
Indian J Ophthalmol; 2023 Dec; 71(12):3652-3657. PubMed ID: 37991299
[TBL] [Abstract][Full Text] [Related]
26. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
Konstas AG; Holló G
Expert Opin Pharmacother; 2016 Jun; 17(9):1271-83. PubMed ID: 27123557
[TBL] [Abstract][Full Text] [Related]
27. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.
Pellinen P; Lokkila J
Ophthalmic Res; 2009; 41(2):118-22. PubMed ID: 19147999
[TBL] [Abstract][Full Text] [Related]
28. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
29. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences.
Bean GW; Camras CB
Surv Ophthalmol; 2008 Nov; 53 Suppl1():S69-84. PubMed ID: 19038626
[TBL] [Abstract][Full Text] [Related]
30. Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.
Pozarowska D
Clin Ophthalmol; 2010 Oct; 4():1229-36. PubMed ID: 21060677
[TBL] [Abstract][Full Text] [Related]
31. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers.
Sutton A; Gouws P; Ropo A
Int J Clin Pharmacol Ther; 2008 Aug; 46(8):400-6. PubMed ID: 18793581
[TBL] [Abstract][Full Text] [Related]
32. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology.
Dueker DK; Singh K; Lin SC; Fechtner RD; Minckler DS; Samples JR; Schuman JS
Ophthalmology; 2007 Sep; 114(9):1779-87. PubMed ID: 17822980
[TBL] [Abstract][Full Text] [Related]
33. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
Sutton A; Gilvarry A; Ropo A
J Ocul Pharmacol Ther; 2007 Aug; 23(4):359-65. PubMed ID: 17803434
[TBL] [Abstract][Full Text] [Related]
34. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma.
Hotehama Y; Mishima HK; Kitazawa Y; Masuda K
Jpn J Ophthalmol; 1993; 37(3):270-4. PubMed ID: 8295364
[TBL] [Abstract][Full Text] [Related]
35. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
37. [Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
Shi JM; Jiang YQ
Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):263-6. PubMed ID: 12575311
[TBL] [Abstract][Full Text] [Related]
38. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.
Brasnu E; Brignole-Baudouin F; Riancho L; Guenoun JM; Warnet JM; Baudouin C
Curr Eye Res; 2008 Apr; 33(4):303-12. PubMed ID: 18398704
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study.
Lee W; Lee S; Bae H; Kim CY; Seong GJ
BMC Ophthalmol; 2017 Apr; 17(1):61. PubMed ID: 28454526
[TBL] [Abstract][Full Text] [Related]
40. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.
van der Valk R; Webers CA; Schouten JS; Zeegers MP; Hendrikse F; Prins MH
Ophthalmology; 2005 Jul; 112(7):1177-85. PubMed ID: 15921747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
